EcoDrugPlus

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSMMDG00005008751
Gene Symbol: LOC115361828
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSMMDG00005020766
Gene Symbol: P2RX3
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSMMDG00005013839
Gene Symbol: P2RX7
1 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSMMDG00005011300
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSMMDG00005010847
Gene Symbol: P2RY12
1 Cross references
180 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSMMDG00005020842
Gene Symbol: P2RY2
1 Cross references
197 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSMMDG00005011224
Gene Symbol: P2RY4
1 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSMMDG00005020859
Gene Symbol: P2RY6
1 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSMMDG00005000623
Gene Symbol: RAMP1
1 Cross references
184 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSMMDG00005015595
Gene Symbol: RAMP1
1 Cross references
191 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMMDG00005021858
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSMMDG00005007160
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).